1. Neonatal lupus: Follow-up in infants with anti-SSA/Ro antibodies and review of the literature
- Author
-
Zuppa, Antonio Alberto, Riccardi, Riccardo, Frezza, Simonetta, Gallini, Francesca, Luciano, Rita Maria Paola, Alighieri, Giovanni, Romagnoli, Costantino, De Carolis, Sara, Zuppa, Antonio Alberto (ORCID:0000-0001-8139-2576), Frezza, Simonetta (ORCID:0000-0001-9314-7818), Gallini, Francesca (ORCID:0000-0002-9510-8481), Luciano, Rita Maria Paola (ORCID:0000-0003-4358-0757), Romagnoli, Costantino (ORCID:0000-0003-1176-2943), De Carolis, Sara (ORCID:0000-0002-5160-7609), Zuppa, Antonio Alberto, Riccardi, Riccardo, Frezza, Simonetta, Gallini, Francesca, Luciano, Rita Maria Paola, Alighieri, Giovanni, Romagnoli, Costantino, De Carolis, Sara, Zuppa, Antonio Alberto (ORCID:0000-0001-8139-2576), Frezza, Simonetta (ORCID:0000-0001-9314-7818), Gallini, Francesca (ORCID:0000-0002-9510-8481), Luciano, Rita Maria Paola (ORCID:0000-0003-4358-0757), Romagnoli, Costantino (ORCID:0000-0003-1176-2943), and De Carolis, Sara (ORCID:0000-0002-5160-7609)
- Abstract
Neonatal Lupus Syndrome (NLS) is a distinct clinical entity caused by transplacental passage of maternal anti-SSA/Ro antibodies (Ab). Mothers may have systemic lupus erythematosus, Sjögren syndrome, or other connective tissue disease, or may be completely healthy at the time of giving birth. NLS includes several clinical manifestations: complete congenital heart block (CCHB) and cutaneous lupus are the most common, while hepatobiliary disease, hematological manifestations and central nervous system involvement may occur. Data from literature on the incidence of the different clinical manifestations of NLS are difficult to compare because they come mostly from retrospective studies or prospective studies, but up to date no systematic follow-up was carried out. We performed a large prospective single-center study with a systematic clinical and instrumental follow-up until 9 months of life, in order to evaluate the incidence and the clinical impact of NLS features. From 2004 to 2014 all infants born in our center to mothers with anti-SSA/Ro Ab were enrolled in a specific diagnostic and follow-up (FU) program. At birth, 50 infants born to mothers with anti-SSA/Ro Ab were found positive for anti-SSA/Ro Ab. Infants were tested for anti SSA/Ro Ab at 3 months of life, if positive they were re-tested at 6 and 9 months. At 9 months anti-SSA/Ro Ab were positive in 10% of children. In two cases (4%) a CCHB was identified during pregnancy and required pacemaker implantation at birth. In 10% of cases a transient ECG alterations was found during follow-up. Hematological NLS features (anemia, neutropenia, thrombocytopenia) were found at birth and during FU in several patients, in all cases without clinical manifestations and in most cases with complete normalization at 9 months. Mild and transient elevation of aminotransferases between 3 and 6 months of life were found in 56% and 40% of patient, respectively; non-specific ultrasound cerebral anomalies
- Published
- 2017